



**Tiermodelle für die Erforschung von
Ess-Störungen**

**Focus Übergewicht
- und was man dagegen tun kann**

T.A. Lutz

**Institute of Veterinary Physiology
Center for Integrative Human Physiology,
University of Zurich
Zurich, Switzerland**

Animal models of eating disorders

- DIO/DR
- Sex differences in eating controls
- Anorexia nervosa
- Binge eating

Animal models of eating disorders

- DIO/DR
- Sex differences in eating controls
- Anorexia nervosa
- Binge eating

Model name	Mutation	Hyperphagia	Decreased Energy Expenditure	Hyperglycemia	Insulin Resistance
MONOGENIC MUTATIONS IN THE LEPTIN PATHWAY					
Leptin and its receptor					
Obesity models with a deficit downstream of the brain leptin receptor (e.g., POMC, MC4 receptor, etc.)					
OTHER MONOGENIC MODELS					
DIET-INDUCED MODELS; POLYGENIC MODELS					
OTHER GENETICALLY ENGINEERED MUTANTS					
SURGICAL OR CHEMICAL MODELS OF OBESITY					
SEASONAL MODELS OF OBESITY					
OTHER MODELS OF OBESITY AND ASSOCIATED METABOLIC CHANGES					

Overview of animal models of obesity


Lutz TA, Woods SC

Curr Protoc Pharmacol. 2012; chapter 5: Unit 5.61


DIO and DR rats

- ❑ Selectively bred from a outbred rat population.
- ❑ On low fat (13.5%) chow diet, DIO and DR rats have the same amount of carcass fat.
- ❑ On low fat diet, DIO rats are bigger than DR rats.
- ❑ When put on 31.5% fat diet, DIO [but not DR] rats become hyperphagic and obese, leptin and insulin-resistant.
- ❑ The DIO phenotype is inherited in a *polygenic* fashion.





DIO rats do not correct adequately for increased fat in their diet



Body weight gain under low and high fat diet



DIO rats have reduced leptin (and insulin) sensitivity before they become obese



In dogs:
Broussard et al. Insulin access to skeletal muscle is impaired during the early stages of diet-induced obesity. *Obesity*, 2016
doi: 10.1002/oby.21562.

Levin et al, 1997, 2003, 2007
Bouret et al, 2008
Gorski et al, 2007

Animal models of eating disorders


- DIO/DR
- Sex differences in eating controls
- Anorexia nervosa
- Binge eating

Obesity in women



1. Loss of estradiol (surgical ovariectomy or menopause) leads to increases in adiposity
2. There is a sex difference in obesity:
more women are morbidly obese than men
3. There is a sex difference in number of gastric bypass surgical procedures:

Population	Time interval						Trend <i>P</i> value
	1987–1989	1990–1992	1993–1995	1996–1998	1999–2001	2002–2004	
Gender							
Females, N = 35,178 (85)	3674 (88)	3687 (87)	5655 (86)	4750 (84)	9346 (85)	8606 (83)	<.0001
Males, N = 6,142 (15)	506 (12)	539 (13)	889 (14)	900 (16)	1605 (15)	1703 (17)	


In females, eating decreases during the peri-ovulatory phase of the ovarian cycle (estrus)



Estradiol is sufficient to normalize food intake & body weight in ovariectomized (OVX) rats



Intact OVX/E2



Asarian &
Geary, 2002


Animal models of eating disorders

- DIO/DR
- Sex differences in eating controls
- **Anorexia nervosa**
- Binge eating





body weight homeostasis


increased food intake during exercise



Voluntary running activity: 5 km/day (females in estrus: > 20 km/day)




Hyperactivity in anorexia nervosa



Effect of food restriction and wheel running activity on BW and estrus cycle

Rats with wheels Rats without wheels



Daily food intake (g)

8.2±0.9

7.9±0.2

Food intake suppression (% of baseline)

62.7±4.25

55.1±1.2

Total body weight loss (g)

54.2±4.3^a

21.3±2.8

Body weight suppression (% of baseline)

24.1±2.3^b

10.0±1.1

Daily activity (revolution)

8186±739^c

-

Increase in activity (% of baseline)

23.6


-

Disruption in estrous cyclicity (%)

100

0

Leptin decreases hyperactivity in severely food restricted rats (60% of ad lib intake for 7d) but not in ad libitum fed rats





Hebebrand et al., 2003
See also:
Hillebrand et al., 2008

Animal models of eating disorders

- DIO/DR
- Sex differences in eating controls
- Anorexia nervosa
- Binge eating


Binge eating model



Restriction: 66% of chow intake on days 1-4 and free-feeding on days 5-8 of each binge cycle


Frustration stress: presentation of (inaccessible) Nutella jar

Estrogen attenuates binge eating response in female OVX rats




□ No estrus
■ Estrus

Not only obesity, but the extent of obesity also increases




Farooqi and O'Rahilly, 2004

Efficient weight loss and maintenance after bariatric surgery, in particular RYGB



RYGB and VSG surgery


César Roux, 1857 - 1934




RYGB surgery




Stylopoulos et al., 2009




Bueter et al., 2010



Development of body weight after surgery



Spontaneous average food intake in SHAM and RYGB rats



* no significant alteration of fecal nutrient content

Sham-operated controls




BWM




RYGB





Baseline energy expenditure in SHAM and RYGB rats





Baseline energy expenditure in SHAM and RYGB rats at different ambient temperatures



Spontaneous average food intake in SHAM and RYGB rats



Meal pattern in SHAM and RYGB rats




Sham-operated controls



RYGB




Spontaneous average food intake in SHAM and RYGB rats: reduced eating is not primarily due to mechanical restriction*




* See also:
no significant alteration
of fecal nutrient content

Spontaneous average food intake in SHAM and VSG rats:
It is unlikely that reduced eating is primarily due to mechanical restriction




By courtesy: Adam Chambers

Spontaneous average food intake in SHAM and VSG rats:
It is unlikely that reduced eating is primarily due to mechanical restriction




Food restriction to 73%
for 22 days




Food intake during first 24h
of refeeding

Atkinson's experiment: the eating inhibitory effect of intestinal bypass depends on plasma-derived factors




Atkinson's experiment



BP

* no effect after administration of plasma from fasted rats



GI hormones are changed after RYGB: PYY and GLP-1 after RYGB in humans in good versus poor responders





GI hormones are changed after RYGB: Blockade of gut hormone release with Octreotide

RYGB bypass



control = Gastric banding



Resolution of Type 2 Diabetes




Resolution of Type 2 Diabetes



What is the role of GLP-1 in postprandial metabolic changes after RYGB?

RYGB versus intensive life style treatment




Vetter et al, 2015
Responses to liquid a meal test in RYGB patients versus Intensive Lifestyle Modification

before
 after 10% BW loss; with exendin-9
 after 10% BW loss; no exendin-9

See also
 Shah et al 2014
 Jimenez et al 2014
 Jackness et al 2013


Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β -cell function in type 2 diabetic patients

Bariatric surgery reduces cardiovascular events



Sjöström et al
JAMA 2012

Superoxide anions



RYGB improves endothelial and HDL function:

Endothelium:

- increased NO production
- reduced oxidative stress

HDL:

- increased eNOS activity
- increased NO production
- reduced VCAM expression
- improved antioxidative properties
- improved cholesterol efflux

Correction of periprandial hyper- and hypoglycemia is clinically relevant


- Disruptions in glucose homeostasis can continue even years after RYGB and can lead to relapse of diabetes.
- Patients undergoing RYGB spent significantly more time in hyper- and hypoglycemic states than those undergoing sleeve gastrectomy

TABLE 2. Clinical Characteristics and Data From Continuous Glucose Monitoring in Subjects in Remission of T2DM After Roux-en-Y RYGBP or SG

	RYGBP (n = 8)	SG (n = 8)	P
Gender, M/F	1/7	3/5	0.248
Age, yr	49.2 ± 13.0	47.2 ± 6.8	0.707
Duration of T2DM before surgery, median (IQR), yr	3 (1.2–5.5)	2.5 (1.0–8.7)	0.750
Time of postsurgical follow-up, yr	2.8 ± 1.5	2.5 ± 0.6	0.622
BMI at evaluation, Kg/m ²	28.5 ± 2.7	30.4 ± 7.7	0.522
HbA1c at evaluation, %	5.5 ± 0.5	5.6 ± 0.4	0.781
Average IG, mg/dL	98.7 ± 8.0	97.7 ± 8.8	0.816
Minimum IG, mg/dL	53.1 ± 12.1	66.4 ± 12.0	0.045
SD, mg/dL	30.6 ± 10.4	15.1 ± 4.2	0.003
Maximum IG, mg/dL	229.6 ± 41.8	153.7 ± 22.4	<0.001
Time in hyperglycemia, % > 160 mg/dL	4.6 ± 3.3	0.4 ± 1.1	0.009
Time in hypoglycemia, % < 70 mg/dL	12.7 ± 8.6	3.2 ± 4.1	0.019
Time in euglycemia, %	82.6 ± 11.0	96.4 ± 4.0	0.007


SD indicates standard deviation.

GLP-1 may play a role in the exaggerated postprandial glucose excursions after RYGB






Does RYGB alter meal-induced glucose excursions in rats?

- 12 male Sprague Dawley rats (450-550 g)
- Housed in cages equipped with BioDAQ food intake monitoring system
- Rats maintained on standard chow
- Intravascular glucose telemetry sensor (DSI) transmitted glucose data every 30-60s







RYGB increases prandial glucose excursions: Refeeding after 6-hour fast


Periprandial Analysis Parameters (1-h post-meal initiation)




RYGB increases prandial glucose excursions: Spontaneous nocturnal meals




Bone mineral density (BMD) decreases rapidly post RYGB



SHAM



SHAM BWM



RYGB

Mechanisms:

- Temporary reduction in Ca absorption
- Increased (sustained) renal Ca losses
- Reduced 25-Vit D
- Massive increase in 1,25-Vit D
- Metabolic (lactic) acidosis

Acknowledgements

Centre for Molecular Cardiology, University of Zurich, University Heart Center, Cardiology, University Hospital Zürich
E Osto, P Doytcheva, CM Matter, TF Lüscher

Institute of Veterinary Physiology, Vetsuisse Faculty, University Zurich
C Corteville, E Tarasco, Bächler T

Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zürich
M Büter, D Vetter

Institute of Clinical Chemistry, University Hospital Zürich
A von Eckardstein, L Rohrer, R Hasballa

Institut Pasteur de Lille, Lille, France
B Staels, S Colin, A Tailleux

Department of Pharmacology & Pharmacy, LKS Faculty of Medicine, The University of Hong Kong
PM Vanhoutte

Institute of Cardiovascular Science, University College London, London, UK
E McLoughlin, M Charakida, JE Deanfield

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy
F Tona

Funding of our RYGB program: ZIHP (Center for Integrated Human Physiology, UZH);
Swiss National Science Foundation; Forschungskredit UZH; National Institutes of Health; EU FP7